India's Chemist Strike 2026: E-Pharmacy Regulation & the Healthcare Access Debate

Origins: The Drugs & Cosmetics Act, 1940

India's pharmaceutical regulation traces its origins to the Chopra Committee (1930), which documented widespread adulteration and misbranding of medicines. The resultant Drugs Act, 1940 — later known as the Drugs and Cosmetics Act, 1940 (DCA) — came into force in April 1947. It established the regulatory framework for import, manufacture, distribution and sale of drugs, creating the Schedule H (prescription-only drugs), Schedule X (psychotropics and habit-forming drugs), and Schedule K (exemptions). The DCA has been amended multiple times — Ayurvedic, Siddha and Unani inclusion (1964); spurious drug penalties (1982); medical device regulation (2020) — but its fundamental architecture is 85 years old.

The critical weakness: the DCA was designed for brick-and-mortar pharmacies. It has no statutory definition of "e-pharmacy" and no explicit framework for online medicine sales, creating the regulatory vacuum that the AIOCD crisis now exposes.

Issue 1: Deep Discounting and DPCO Circumvention

The Drug Price Control Order (DPCO) 2013 fixes the retail margin on NLEM (National List of Essential Medicines) drugs at 16% for retailers and 8% for wholesalers. E-pharmacy platforms, however, offer consumers discounts of 20–50% — structurally impossible within the DPCO margin framework unless funded externally. AIOCD alleges that platforms like Tata 1mg, PharmEasy, Netmeds, Apollo Pharmacy, and quick-commerce players sustain these discounts through venture capital burning to capture market share — a predatory pricing strategy that brick-and-mortar chemists operating on tight margins cannot compete with. This is not merely a trade complaint; it undermines the regulatory intent of DPCO, which was designed to ensure affordable medicines are available through a sustainable distribution network.

Issue 2: Prescription Verification Failure and AI-Generated Fraud

The Drugs and Cosmetics Act mandates that Schedule H, H1, and X medicines be dispensed only against a valid prescription from a registered medical practitioner. A February 2026 investigation by the Times of India found that several online pharmacy platforms accepted AI-generated prescriptions bearing fabricated hospital names and doctor details to dispense psychotropic drugs, opioids, antibiotics, and Schedule X medicines. Unlike a neighbourhood chemist — who can visually assess prescription authenticity, recognize regular customers, and exercise professional judgment — online platforms rely on automated upload-and-approve systems with limited human oversight. AIOCD identified three structural patient safety gaps: AI-fabricated prescriptions that lack human verification, prescription reuse (same scanned Rx used multiple times for controlled drugs), and no central prescription registry to detect duplicates.

Issue 3: Antimicrobial Resistance (AMR) and Public Health Risk

India already bears the largest AMR burden in the world, with antibiotic resistance responsible for approximately 700,000 deaths annually globally (WHO). The unchecked online sale of antibiotics — particularly Schedule H1 drugs like carbapenems and cephalosporins — without prescription validation accelerates AMR by enabling self-medication and incomplete treatment courses. PM Modi himself referenced AMR in a Mann Ki Baat address preceding the strike, acknowledging the unchecked sale of antibiotics as a public health emergency. AIOCD explicitly cited the AMR link in its February 2026 letter to the PMO, arguing that closing this channel was non-negotiable for India's long-term public health trajectory.

Issue 4: COVID-Era GSR 220(E) — A Pandemic Loophole That Never Closed

The central regulatory grievance is the Government Notification GSR 220(E), introduced in March 2020 during the COVID-19 lockdown to facilitate home delivery of medicines by relaxing prescription verification requirements. The justification was unimpeachable during the pandemic. However, the notification was never formally withdrawn after the pandemic ended, effectively creating a permanent statutory relaxation that e-pharmacies leveraged to continue operating with minimal prescription checks. Simultaneously, the draft GSR 817(E) e-pharmacy rules — which proposed a comprehensive licensing and verification framework — were never notified, leaving a legal vacuum: a relaxation in force, but the regulatory framework meant to accompany it absent.

Issue 5: Rural Healthcare Infrastructure Dependence

The neighbourhood pharmacy is structurally embedded in rural India's healthcare delivery in ways that e-pharmacies cannot yet replicate. Rural Health Statistics 2021 document a 76% shortage of specialists at Community Health Centres and 5% of PHCs functioning without doctors. In this environment, the local chemist often provides the first consultation, identifies drug interactions, and maintains medicine availability chains for conditions from hypertension to tuberculosis. If rural chemists close because they cannot compete with deep-discounting e-pharmacies, the resulting healthcare access gap would fall hardest on the very population — poor, rural, elderly — who are least equipped to access digital platforms. AIOCD estimates rural and semi-urban chemists face the greatest closure risk.

Social Implication 1: Erosion of Last-Mile Healthcare for the Vulnerable

The neighbourhood pharmacy is India's most democratic healthcare touchpoint — no appointment, no travel, no literacy barrier to ask a question. Its erosion would disproportionately harm the elderly, the chronically ill, the rural poor, and persons with disabilities, who rely on it not just for medicines but for ongoing medication guidance. A 2023 George Institute study found that while urban e-pharmacy platforms cover 22,000+ pin codes, their model is primarily urban-first. Rural delivery infrastructure, cold-chain compliance for temperature-sensitive medicines, and last-mile reach remain far below what traditional pharmacies provide. The digital divide — low smartphone penetration, limited internet access, low health literacy in rural areas — ensures that a pharmacy sector restructured around e-commerce will systematically exclude the most vulnerable.

Economic Implication: 5 Crore Livelihoods and the Gig Substitution

AIOCD estimates that the pharmacy retail trade — across owners, employees, distributors, and ancillary support — sustains approximately 5 crore (50 million) livelihoods. These are predominantly small family-owned businesses concentrated in Tier-2 and Tier-3 cities and rural areas. The displacement of this workforce by platform-based models does not result in equivalent new employment: gig-based delivery workers in the e-pharmacy model earn significantly less, lack social security, and face algorithmic precarity. This is a specific instantiation of the broader platform economy vs. informal sector challenge that UPSC regularly interrogates in Indian Society answers.

Public Health Implication: AMR, Drug Abuse & Patient Safety

The most consequential long-term implication of unregulated e-pharmacies is the acceleration of antimicrobial resistance. India's already alarming AMR burden — it uses the most antibiotics globally by volume — is being aggravated by the ease of obtaining antibiotics online without prescriptions. The AI-prescription loophole extends this to psychotropic drugs and opioids, creating channels for prescription drug abuse that are difficult to monitor or reverse. Further, online platforms operating without cold-chain monitoring, expiry-date verification, or pharmacist consultation create systematic risks of counterfeit and sub-standard medicine distribution at scale. The 2025 India cough syrup crisis — in which children died after consuming medicines contaminated with diethylene glycol in Madhya Pradesh and Rajasthan — underscores the real-world cost of pharmaceutical supply-chain regulatory gaps.

Governance Implication: Judicial Orders, Executive Inaction & Regulatory Capture

The failure to notify the e-pharmacy framework for 8 years — despite a Delhi HC injunction, multiple CDSCO show-cause notices, parliamentary questions, and AIOCD representations — raises the spectre of regulatory capture: the possibility that large e-pharmacy and quick-commerce platforms, backed by corporate interests, have influenced the regulatory timeline to their advantage. The Ministry of Health's own 2022 RTI response — that finalisation of e-pharmacy rules "may not be possible to say any timelines at this stage" — is a remarkable admission of deliberate regulatory inertia on a patient safety matter.

Judicial Initiatives

Indian courts have been the primary catalysts for action, filling the legislative vacuum through judicial oversight — a classic feature of India's governance landscape that Mains answers should explicitly note.

Legislative and Regulatory Initiatives

Beyond the courts, the following policy actions constitute the landscape of initiatives — though notably, the most critical one (finalization of e-pharmacy rules) remains incomplete.

The Global Pattern: Market Expansion Ahead of Regulation

India is not unique in facing the e-pharmacy regulation challenge. A George Institute study (2023) found that e-pharmacy markets globally have "expanded faster than the pace of regulation, particularly in low- and middle-income countries." However, developed economies have moved faster to create regulatory architecture, and their models offer instructive templates for India's way forward.